Q-omics provides the consensus-scored EIF3J-DT profile across patient tissues and cancer cell-line models. EIF3J-DT expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EIF3J-DT is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, EIF3J-DT RNA expression shows 20,659 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LUAD, and ACC as cancer lineages where EIF3J-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF3J-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF3J-DT survival associations across molecular data types. EIF3J-DT RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF3J-DT RNA expression–survival associations across cancer types. High EIF3J-DT expression shows unfavorable associations in COAD, LIHC and ACC, but favorable associations in KIRC, READ and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EIF3J-DT RNA expression.
This table summarizes EIF3J-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for EIF3J-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF3J-DT shows lower tumor expression in LUAD, KICH, LUSC, UCEC and BRCA and higher tumor expression in LIHC. The LUAD box plot shows higher EIF3J-DT RNA expression in normal versus tumor tissue (log2 FC = −0.617, t-test p < 0.001).
This table shows molecular features associated with EIF3J-DT in patient tissues and cancer cell lines. In patient samples, EIF3J-DT shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
